Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Buy rating on Natera, retaining the price target of $285.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kyle Mikson CFA has given his Buy rating due to a combination of factors tied to Natera’s consistently strong execution and outlook. He highlights that the company delivered another quarter of revenue and volume growth ahead of expectations, with record adoption of Signatera driving improved margins and overall profitability trends, while management issued 2026 guidance that still appears conservative relative to current momentum.
He also points to multiple growth catalysts in both oncology and women’s health, including expanded Medicare coverage, AI-driven cost efficiencies, and the launch of new and enhanced tests such as the broadened Fetal Focus sgNIPT, all supported by a step-up in R&D investment and an inflection to positive cash flow in 2026. In his view, this combination of robust near-term performance, underappreciated upside to guidance, and a rich innovation pipeline supports further upside in Natera’s shares and justifies maintaining a Buy rating and a $285 price target.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $280.00 price target.
Based on the recent corporate insider activity of 197 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NTRA in relation to earlier this year.